Skip to main content
SpringerLink
Log in

The Endocannabinoid System is a Major Player in Schizophrenia

  • Chapter
Cannabinoids and the Brain

Converging lines of evidence point to an inextricable role of the endocannabinoid system in schizophrenia. Marijuana consumption (1) elicits psychotic symptoms similar to schizophrenia; (2) precipitates schizophrenia in susceptible individuals; (3) worsens psychosis; and (4) is more prevalent among schizophrenia patients. (5) Genetic linkage studies have mapped a locus around the CB1 cannabinoid receptor gene (CNR1), which potentially confers susceptibility to schizophrenia, and (6) within CNR1, several polymorphisms reportedly associate with this disease. (7) The endocannabinoid system controls brain areas and signalling systems implicated in schizophrenia, (8) and is overactive in patients, (9). It correlates with symptom severity and is reversible with certain antipsychotics. Finally, (10) the naturally occurring CB1 receptor antagonist cannabidiol exhibits a promising antipsychotic profile in pharmacological model-psychoses and schizophrenia. In summarizing the pertinent epidemiological and molecular data, we define schizophrenia as a manifestation of aberrant circuitry formation at the synaptic level and propose that the liability to develop psychosis is driven by imbalanced co-signalling between endocannabinoids and other neuromodulatory pathways already implicated in schizophrenia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Adler LE, Olincy A, Waldo M, Harris JG, Griffith J, Stevens K, Flach K, Nagamoto H, Bickford P, Leonard S, Freedman R (1998) Schizophrenia, sensory gating, and nicotinic receptors. Schizophr Bull 24:189–202.

    PubMed  CAS  Google Scholar 

  • Aldrich MR (1977) Tantric cannabis use in India. J Psychedelic Drugs 9:227–233.

    Google Scholar 

  • Andersson M, Usiello A, Borgkvist A, Pozzi L, Dominguez C, Fienberg AA, Svenningsson P, Fredholm BB, Borrelli E, Greengard P, Fisone G (2005) Cannabinoid action depends on phosphorylation of dopamine- and cAMP-regulated phosphoprotein of 32 kDa at the protein kinase A site in striatal projection neurons. J Neurosci 25:8432–8438.

    Article  PubMed  CAS  Google Scholar 

  • Andreasson S, Allebeck P, Engstrom A, Rydberg U (1987) Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2:1483–1486.

    Article  PubMed  CAS  Google Scholar 

  • Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002) Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ 325:1212–1213.

    Article  PubMed  Google Scholar 

  • Arseneault L, Cannon M, Witton J, Murray RM (2004) Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiatry 184:110–117.

    Article  PubMed  Google Scholar 

  • Arvindakshan M, Sitasawad S, Debsikdar V, Ghate M, Evans D, Horrobin DF, Bennett C, Ranjekar PK, Mahadik SP (2003) Essential polyunsaturated fatty acid and lipid peroxide levels in never-medicated and medicated schizophrenia patients. Biol Psychiatry 53:56–64.

    Article  PubMed  CAS  Google Scholar 

  • Baldelli P, Hernandez-Guijo JM, Carabelli V, Carbone E (2005) Brain-derived neurotrophic factor enhances GABA release probability and nonuniform distribution of N- and P/Q-type channels on release sites of hippocampal inhibitory synapses. J Neurosci 25:3358–3368.

    Article  PubMed  CAS  Google Scholar 

  • Ballmaier M, Bortolato M, Rizzetti C, Zoli M, Gessa G, Heinz A, Spano P (2007) Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis. Neuropsychopharmacology 32:2098–2107.

    Article  PubMed  CAS  Google Scholar 

  • Bär KJ, Letzsch A, Jochum T, Wagner G, Greiner W, Sauer H (2005) Loss of efferent vagal activity in acute schizophrenia. J Psychiatr Res 39:519–527.

    Article  PubMed  Google Scholar 

  • Baudelaire C (1966) Les Paradis Artificiels. Paris: Garnier-Flammarion.

    Google Scholar 

  • Berghuis P, Dobszay MB, Wang X, Spano S, Ledda F, Sousa KM, Schulte G, Ernfors P, Mackie K, Paratcha G, Hurd YL, Harkany T (2005) Endocannabinoids regulate interneuron migration and morphogenesis by transactivating the TrkB receptor. Proc Natl Acad Sci USA 102:19115–191120.

    Article  PubMed  CAS  Google Scholar 

  • Berghuis P, Rajnicek AM, Morozov YM, Ross RA, Mulder J, Urban GM, Monory K, Marsicano G, Matteoli M, Canty A, Irving AJ, Katona I, Yanagawa Y, Rakic P, Lutz B, Mackie K, Harkany T (2007) Hardwiring the brain: endocannabinoids shape neuronal connectivity. Science 316:1212–1216.

    Article  PubMed  CAS  Google Scholar 

  • Bergson C, Levenson R, Goldman-Rakic PS, Lidow MS (2003) Dopamine receptor-interacting proteins: the Ca2+ connection in dopamine signaling. Trends Pharmacol Sci 24:486–492.

    Article  PubMed  CAS  Google Scholar 

  • Berridge MJ (1998) Neuronal calcium signaling. Neuron 21:13–26.

    Article  PubMed  CAS  Google Scholar 

  • Betz VA (1875) Two centers in the human brain cortex.

    Google Scholar 

  • Blackwood D (2000) P300, a state and a trait marker in schizophrenia. Lancet 355:771–72.

    Article  PubMed  CAS  Google Scholar 

  • Bleuler E (1911) Handbuch der Psychiatrie. Dementia praecox oder Gruppe der Schizophrenien. Leipzig: Deuticke.

    Google Scholar 

  • Blum J, Braverman ER, Dinardo MJ, Wood RC, Sheridan PJ (1994) Prolonged P300 latency in a neuropsychiatric population with the D2 dopamine receptor A1 allele. Pharmacogenetics 4:313–322.

    Article  PubMed  CAS  Google Scholar 

  • Boksa P (2007) Of rats and schizophrenia. J Psychiatry Neurosci 32:8–10.

    PubMed  Google Scholar 

  • Boucher AA, Arnold JC, Duffy L, Schofield PR, Micheau J, Karl T (2007) Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. Psychopharmacology (Berl) 192:325–336.

    Article  CAS  Google Scholar 

  • Boydell J, van Os J, Caspi A, Kennedy N, Giouroukou E, Fearon P, Farrell M, Murray RM (2006) Trends in cannabis use prior to first presentation with schizophrenia, in South-East London between 1965 and 1999. Psychol Med 36:1441–1446.

    Article  PubMed  CAS  Google Scholar 

  • Brakeman PR, Lanahan AA, O’Brien R, Roche K, Barnes CA, Huganir RL, Worley PF (1997) Homer: a protein that selectively binds metabotropic glutamate receptors. Nature 368:284–288.

    Article  Google Scholar 

  • Brown P, Williams D, Aziz T, Mazzone P, Oliviero A, Insola A, Tonali P, Di Lazzaro V (2002) Pallidal activity recorded in patients with implanted electrodes predictively correlates with eventual performance in a timing task. Neurosci Lett 330:188–192.

    Article  PubMed  CAS  Google Scholar 

  • Buhusi CV, Meck WH (2005) What makes us tick? Functional and neural mechanisms of interval timing. Nat Rev Neurosci 6:755–765.

    Article  PubMed  CAS  Google Scholar 

  • Burgoyne RD, O’Callaghan DW, Hasdemir B, Haynes LP, Tepikin AV (2004) Neuronal Ca2+-sensor proteins: multitalented regulators of neuronal function. Trends Neurosci 27:203–209.

    Article  PubMed  CAS  Google Scholar 

  • Cannon TD, Thompson PM, van Erp TG, Toga AW, Poutanen VP, Huttunen M, Lonnqvist J, Standerskjold-Nordenstam CG, Narr KL, Khaledy M, Zoumalan CI, Dail R, Kaprio J (2002) Cortex mapping reveals regionally specific patterns of genetic and disease-specific gray-matter deficits in twins discordant for schizophrenia. Proc Natl Acad Sci USA 99:3228–3233.

    Article  PubMed  CAS  Google Scholar 

  • Cao Q, Martinez M, Zhang J, Sanders AR, Badner JA, Cravchik A, Markey CJ, Beshah E, Guroff JJ, Maxwell ME, Kazuba DM, Whiten R, Goldin LR, Gershon ES, Gejman PV (1997) Suggestive evidence for a schizophrenia susceptibility locus on chromosome 6q and a confirmation in an independent series of pedigrees. Genomics 43:1–8.

    Article  PubMed  CAS  Google Scholar 

  • Carr DB, Surmeier DJ (2007) M1 Muscarinic receptor modulation of kir2 channels enhances temporal summation of excitatory synaptic potentials in prefrontal cortex pyramidal neurons. J Neurophysiol 97:3432–3438.

    Article  PubMed  CAS  Google Scholar 

  • Carriba P, Ortiz O, Patkar K, Justinova Z, Stroik J, Themann A, Müller C, Woods AS, Hope BT, Ciruela F, Casadó V, Canela EI, Lluis C, Goldberg SR, Moratalla R, Franco R, Ferré S (2007) Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacol doi:10.1038/sj.npp. 1301375.

    Google Scholar 

  • Chapman J (1966) The early symptoms of schizophrenia. Br J Psychiatry 112:225–251.

    Article  PubMed  CAS  Google Scholar 

  • Chaudry HR, Moss HB, Bashir A, Suliman T (1991) Cannabis psychosis following bhang ingestion. Br J Addict 86:1075–1081.

    Article  PubMed  CAS  Google Scholar 

  • Cheer JF, Cadogan AK, Marsden CA, Fone KC, Kendall DA (1999) Modification of 5-HT2 receptor mediated behaviour in the rat by oleamide and the role of cannabinoid receptors. Neuropharmacology 38:533–541.

    Article  PubMed  CAS  Google Scholar 

  • Cheer JF, Wassum KM, Heien ML, Phillips PE, Wightman RM (2004) Cannabinoids enhance subsecond dopamine release in the nucleus accumbens of awake rats. J Neurosci 24:4393–4400.

    Article  PubMed  CAS  Google Scholar 

  • Cheer JF, Wassum KM, Sombers LA, Heien ML, Ariansen JL, Aragona BJ, Phillips PE, Wightman RM (2007) Phasic dopamine release evoked by abused substances requires cannabinoid receptor activation. J Neurosci 27:791–795.

    Article  PubMed  CAS  Google Scholar 

  • Chen N, Appell M, Berfield JL, Reith ME (2003) Inhibition by arachidonic acid and other fatty acids of dopamine uptake at the human dopamine transporter. Eur J Pharmacol 478:89–95.

    Article  PubMed  CAS  Google Scholar 

  • Chen L, Bohanick JD, Nishihara M, Seamans JK, Yang CR (2007) Dopamine D1/5 receptor-mediated long-term potentiation of intrinsic excitability in rat prefrontal cortical neurons: Ca2+-dependent intracellular signaling. J Neurophysiol 97:2448–2464.

    Article  PubMed  CAS  Google Scholar 

  • Chen ZY, Patel PD, Sant G, Meng CX, Teng KK, Hempstead BL, Lee FS (2004) Variant brain-derived neurotrophic factor(BDNF)(Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. J Neurosci 24:4401–4411.

    Article  PubMed  CAS  Google Scholar 

  • Chevaleyre V, Takahashi KA, Castillo PE (2006) Endocannabinoid-mediated synaptic plasticity in the CNS. Annu Rev Neurosci 29:37–76.

    Article  PubMed  CAS  Google Scholar 

  • Comings DE, Muhleman D, Gade R, Johnson P, Verde R, Saucier G, MacMurray J (1997) Cannabinoid receptor gene (CNR1): association with i.v. drug use. Mol Psychiatry 2:161–168.

    Article  PubMed  CAS  Google Scholar 

  • Cuffel BJ (1992) Prevalence estimates of substance abuse in schizophrenia and their correlates. J Nerv Ment Dis 180:589–592.

    Article  PubMed  CAS  Google Scholar 

  • Cui G, Bernier BE, Harnett MT, Morikawa H (2007) Differential regulation of action potential- and metabotropic glutamate receptor-induced Ca2+ signals by inositol 1, 4, 5-trisphosphate in dopaminergic neurons. J Neurosci 27:4776–4785.

    Article  PubMed  CAS  Google Scholar 

  • Damasio AR (1999) The Feeling of What Happens–Body and Emotion in the Making of Consciousness. New York: Harcourt Brace.

    Google Scholar 

  • Damasio AR, Grabowski TJ, Bechara A, Damasio H, Ponto LL, Parvizi J, Hichwa RD (2000) Subcortical and cortical brain activity during the feeling of self-generated emotions. Nat Neurosci 3:1049–1056.

    Article  PubMed  CAS  Google Scholar 

  • Dawson E (1995) Identification of a polymorphic triplet repeat marker for the brain cannabinoid receptor gene: use in linkage and association studies. Psychiatr Genet 5(S50–S51):850.

    Article  Google Scholar 

  • De Marchi N, De Petrocellis L, Orlando P, Daniele F, Fezza F, Di Marzo V (2003) Endocannabinoid signaling in the blood of patients with schizophrenia. Lipids Health Dis 2:5.

    Article  PubMed  Google Scholar 

  • Dean B, Sundram S, Bradbury R, Scarr E, Copolov D (2001) Studies on [3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103:9–15.

    Article  PubMed  CAS  Google Scholar 

  • Degroot A, Köfalvi A, Wade MR, Davis RJ, Rodrigues RJ, Rebola N, Cunha RA, Nomikos GG (2006) CB1 receptor antagonism increases hippocampal acetylcholine release: site and mechanism of action. Mol Pharmacol 70:1236–1245.

    Article  PubMed  CAS  Google Scholar 

  • Delmas P, Crest M, Brown DA (2004) Functional organization of PLC signaling microdomains in neurons. Trends Neurosci 27:41–47.

    Article  PubMed  CAS  Google Scholar 

  • Devlin MG, Christopoulos A (2002) Modulation of cannabinoid agonist binding by 5-HT in the rat cerebellum. J Neurochem 80:1095–1102.

    Article  PubMed  CAS  Google Scholar 

  • Drewe M, Drewe J, Riecher-Rossler A (2004) Cannabis and risk of psychosis. Swiss Med Wkly 134:659–663.

    PubMed  Google Scholar 

  • D’Souza DC (2007) Cannabinoids and psychosis. Int Rev Neurobiol 78:289–326.

    Article  PubMed  CAS  Google Scholar 

  • Duarte JM, Nogueira C, Mackie K, Oliveira CR, Cunha RA, Köfalvi A (2007) Increase of cannabinoid CB1 receptor density in the hippocampus of streptozotocin-induced diabetic rats. Exp Neurol 204:479–484.

    Article  PubMed  CAS  Google Scholar 

  • Eblen F, Graybiel AM (1995) Highly restricted origin of prefrontal cortical inputs to striosomes in the macaque monkey. J Neurosci 15:5999–6013.

    PubMed  CAS  Google Scholar 

  • Ellert-Miklaszewska A, Kaminska B, Konarska L (2005) Cannabinoids down-regulate PI3K/Akt and Erk signaling pathways and activate proapoptotic function of Bad protein. Cell Signal 17:25–37.

    Article  PubMed  CAS  Google Scholar 

  • Elvevag B, McCormack T, Gilbert A, Brown GD, Weinberger DR, Goldberg TE (2003) Duration judgements in patients with schizophrenia. Psychol Med 33:1249–1261.

    Article  PubMed  CAS  Google Scholar 

  • Emrich HM, Leweke FM, Schneider U (1997) Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Behav 56:803–807.

    Article  PubMed  CAS  Google Scholar 

  • Freud S (1915) The unconscious. In: Strachey J (ed.), Complete Psychological Works, Vol. 14, translated in 1964. London: Hogarth.

    Google Scholar 

  • Frith CD, Blakemore S, Wolpert DM (2000) Explaining the symptoms of schizophrenia: abnormalities in the awareness of action. Brain Res Brain Res Rev 31:357–363.

    Article  PubMed  CAS  Google Scholar 

  • Fritzsche M, Fritzsche LN, Kosidubova SM, Prognimak AB, Mayorov OY (2006) Asymmetric information-processing in development, evolution and psychopathology. In: Hellige JB, Bogen JE (eds.), Cognition, Brain, Behavior, Special Issue. Napoca: CBB, pp. 311–342.

    Google Scholar 

  • Fujii N, Graybiel AM (2005) Time-varying covariance of neural activities recorded in striatum and frontal cortex as monkeys perform sequential-saccade tasks. Proc Natl Acad Sci USA 102:9032–9037.

    Article  PubMed  CAS  Google Scholar 

  • Fuster JM (1989) The Prefrontal Cortex, Anatomy, Physiology, and Neuropsychology of the Frontal Lobe. New York: Raven.

    Google Scholar 

  • Gardner EL (2002) Addictive potential of cannabinoids: the underlying neurobiology. Chem Phys Lipids 121:267–290.

    Article  PubMed  CAS  Google Scholar 

  • Gerfen CR (2004) Basal ganglia. In: Paxinos G (ed.), The Rat Nervous System. Amsterdam: Elsevier, pp. 455–508.

    Chapter  Google Scholar 

  • Giuffrida A, Leweke FM, Gerth CW, Schreiber D, Koethe D, Faulhaber J, Klosterkotter J, Piomelli D (2004) Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology 29:2108–2114.

    Article  PubMed  CAS  Google Scholar 

  • Gladkevich A, Kauffman HF, Korf J (2004) Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 28:559–576.

    Article  PubMed  Google Scholar 

  • Glass M, Felder CC (1997) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci 17:5327–5333.

    PubMed  CAS  Google Scholar 

  • Goldman-Rakic PS (2005) Working memory dysfunction in schizophrenia. In: Salloway SP, Malloy PF, Duffy JD (eds.), The Frontal Lobes and Neuropsychiatric Illness. Washington, DC: American Psychiatric PI, pp. 71–82.

    Google Scholar 

  • Goto Y, Grace AA (2005a) Dopamine-dependent interactions between limbic and prefrontal cortical plasticity in the nucleus accumbens: disruption by cocaine sensitization. Neuron 47:255–266.

    Article  PubMed  CAS  Google Scholar 

  • Goto Y, Grace AA (2005b) Dopaminergic modulation of limbic and cortical drive of nucleus accumbens in goal-directed behavior. Nat Neurosci 8:805–812.

    Article  PubMed  CAS  Google Scholar 

  • Gottesmann C (2006) The dreaming sleep stage: a new neurobiological model of schizophrenia? Neuroscience 140:1105–1115.

    Article  PubMed  CAS  Google Scholar 

  • Green AL, Wang S, Owen SL, Aziz TZ (2007) The periaqueductal grey area and the cardiovascular system. Acta Neurochir Suppl 97:521–528.

    Article  PubMed  CAS  Google Scholar 

  • Gross A, Joutsiniemi SL, Rimon R, Appelberg B (2006) Correlation of symptom clusters of schizophrenia with absolute powers of main frequency bands in quantitative EEG. Behav Brain Funct 2:23.

    Article  PubMed  Google Scholar 

  • Gu Z, Jiang Q, Yan Z (2007) RGS4 modulates serotonin signaling in prefrontal cortex and links to serotonin dysfunction in a rat model of schizophrenia. Mol Pharmacol 71:1030–1039.

    Article  PubMed  CAS  Google Scholar 

  • Halikas JA, Goodwin DW, Guze SB (1972) Marihuana use and psychiatric illness. Arch Gen Psychiatry 27:162–165.

    PubMed  CAS  Google Scholar 

  • Hampson AJ, Bornheim LM, Scanziani M, Yost CS, Gray AT, Hansen BM, Leonoudakis DJ, Bickler PE (1998) Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J Neurochem 70:671–676.

    Article  PubMed  CAS  Google Scholar 

  • Hanson DR, Gottesman II (2005) Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med Genet 6:7.

    Article  PubMed  CAS  Google Scholar 

  • Häring M, Marsicano G, Lutz B, Monory K (2007) Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. Neuroscience 146:1212–1219.

    Article  PubMed  CAS  Google Scholar 

  • Harkány T, Guzman M, Galve-Roperh I, Berghuis P, Devi LA, Mackie K (2007) The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci 28:83–92.

    Article  PubMed  CAS  Google Scholar 

  • Hashimoto T, Bergen SE, Nguyen QL, Xu B, Monteggia LM, Pierri JN, Sun Z, Sampson AR, Lewis DA (2005) Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J Neurosci 25:372–383.

    Article  PubMed  CAS  Google Scholar 

  • Hashimoto T, Lewis DA (2006) BDNF Val66Met polymorphism and GAD67 mRNA expression in the prefrontal cortex of subjects with schizophrenia. Am J Psychiatry 163:534–537.

    Article  PubMed  Google Scholar 

  • Haznedar MM, Buchsbaum MS, Hazlett EA, Shihabuddin L, New A, Siever LJ (2004) Cingulate gyrus volume and metabolism in the schizophrenia spectrum. Schizophr Res 71:249–262.

    Article  PubMed  Google Scholar 

  • Heath RG (1954) Studies in Schizophrenia. A Multidisciplinary Approach to Mind-Brain Relationships. Cambridge: Harvard University Press.

    Google Scholar 

  • Heath RG (1962) Common characteristics of epilepsy and schizophrenia: clinical observation and depth electrode studies. Am J Psychiatry 118:1013–1026.

    PubMed  CAS  Google Scholar 

  • Henquet C, Murray R, Linszen D, van Os J (2005) The environment and schizophrenia: the role of cannabis use. Schizophr Bull 31:608–612.

    Article  PubMed  Google Scholar 

  • Herkenham M, Lynn AB, Little MD, Johnson MR, Melvin LS, de Costa BR, Rice KC (1990) Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA 87:1932–1936.

    Article  PubMed  CAS  Google Scholar 

  • Herrero MT, Barcia C, Navarro JM (2202) Functional anatomy of thalamus and basal ganglia. Childs Nerv Syst 18:386–404.

    Article  Google Scholar 

  • Hicks RE, Gualtieri CT, Mayo JP, Perez-Reyes M (1984) Cannabis, atropine, and temporal information processing. Neuropsychobiology 12:229–237.

    Article  PubMed  CAS  Google Scholar 

  • Hill EL, Gallopin T, Ferezou I, Cauli B, Rossier J, Schweitzer P, Lambolez B (2007) Functional CB1 receptors are broadly expressed in neocortical GABAergic and glutamatergic neurons. J Neurophysiol 97:2580–2589.

    Article  PubMed  CAS  Google Scholar 

  • Hoehe MR, Caenazzo L, Martinez MM, Hsieh WT, Modi WS, Gershon ES, Bonner TI (1991) Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q14–q15. New Biol 3:880–885.

    PubMed  CAS  Google Scholar 

  • Hoffman DC (1992) Typical and atypical neuroleptics antagonize MK-801-induced locomotion and stereotypy in rats. J Neural Transm Gen Sect 89:1–10.

    Article  PubMed  CAS  Google Scholar 

  • Holstege G, Mouton LJ, Gerrits N (2004). Emotional motor system. In: Paxinos G (ed.), The Human Nervous System. Amsterdam: Elsevier, pp. 1306–1325.

    Chapter  Google Scholar 

  • Hyman SE, Malenka RC, Nestler EJ (2006) Neural mechanisms of addiction: the role of reward-related learning and memory, Annu Rev Neurosci. 2006; 29:565–98.

    Article  PubMed  CAS  Google Scholar 

  • Isohanni M, Miettunen J, Maki P, Murray GK, Ridler K, Lauronen E, Moilanen K, Alaraisanen A, Haapea M, Isohanni I, Ivleva E, Tamminga C, McGrath J, Koponen H (2006) Risk factors for schizophrenia. Follow-up data from the Northern Finland 1966 Birth Cohort Study. World Psychiatry 5:168–171.

    PubMed  Google Scholar 

  • Iversen L (2003) Cannabis and the brain. Brain 126:1252–1270.

    Article  PubMed  Google Scholar 

  • Jackson JH (1932) In: Taylor J (ed.), Selected Writings of John Hughlings Jackson. London: Hodder & Stoughton.

    Google Scholar 

  • Jarrahian A, Watts VJ, Barker EL (2004) D2 dopamine receptors modulate G -subunit coupling of the CB1 cannabinoid receptor. J Pharmacol Exp Ther 308:880–886.

    Article  PubMed  CAS  Google Scholar 

  • Jiang W, Zhang Y, Xiao L, Van Cleemput J, Ji SP, Bai G, Zhang X (2005) Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 115:3104–3116.

    Article  PubMed  CAS  Google Scholar 

  • Jin K, Xie L, Kim SH, Parmentier-Batteur S, Sun Y, Mao XO, Childs J, Greenberg DA (2004) Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol Pharmacol 66:204–208.

    Article  PubMed  CAS  Google Scholar 

  • Jockers-Scherubl MC, Danker-Hopfe H, Mahlberg R, Selig F, Rentzsch J, Schurer F, Lang UE, Hellweg R (2004) Brain-derived neurotrophic factor serum concentrations are increased in drug-naive schizophrenic patients with chronic cannabis abuse and multiple substance abuse. Neurosci Lett 371:79–83.

    Article  PubMed  CAS  Google Scholar 

  • Jockers-Scherubl MC, Matthies U, Danker-Hopfe H, Lang UE, Mahlberg R, Hellweg R (2003) Chronic cannabis abuse raises nerve growth factor serum concentrations in drug-naive schizophrenic patients. J Psychopharmacol 17:439–445.

    Article  PubMed  Google Scholar 

  • Jockers-Scherubl MC, Rentzsch J, Danker-Hopfe H, Radzei N, Schurer F, Bahri S, Hellweg R (2006) Adequate antipsychotic treatment normalizes serum nerve growth factor concentrations in schizophrenia with and without cannabis or additional substance abuse. Neurosci Lett 400:262–266.

    Article  PubMed  CAS  Google Scholar 

  • Johns A (2001) Psychiatric effects of cannabis. Br J Psychiatry 178:116–122.

    Article  PubMed  CAS  Google Scholar 

  • Johnson JP, Muhleman D, Mc Murray J, Gade R, Verde R, Ask M, Kelley J, Comings DE (1997) Association between the cannabinoid receptor gene (CNR1) and the P300 event-related potential. Mol Psychiatry 2:169–171.

    Article  PubMed  CAS  Google Scholar 

  • Jones EG (2007) The Thalamus. California: Cambridge University Press.

    Google Scholar 

  • Joyce JN, Gurevich EV (1999) D3 receptors and the actions of neuroleptics in the ventral striatopallidal system of schizophrenics. Ann NY Acad Sci 877:595–613.

    Article  PubMed  CAS  Google Scholar 

  • Kaiya H, Nishida A, Imai A, Nakashima S, Nozawa Y (1989) Accumulation of diacylgylcerol in platelet phosphoinositide turnover in schizophrenia: a biological marker of good prognosis? Biol Psychiatry 26:669–676.

    Article  PubMed  CAS  Google Scholar 

  • Kalkman HO (2006) The role of the phosphatidylinositide 3-kinase-protein kinase B pathway in schizophrenia. Pharmacol Ther 110:117–134.

    Article  PubMed  CAS  Google Scholar 

  • Kang H, Schuman EM (1995) Long-lasting neurotrophin-induced enhancement of synaptic transmission in the adult hippocampus. Science 267:1658–1662.

    Article  PubMed  CAS  Google Scholar 

  • Kapur S, Remington G (2001) Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 52:503–517.

    Article  PubMed  CAS  Google Scholar 

  • Kapur S, Remington G (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153:466–476.

    PubMed  CAS  Google Scholar 

  • Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P (2000) A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 57:553–559.

    Article  PubMed  CAS  Google Scholar 

  • Katona I, Sperlágh B, Magloczky Z, Santha E, Köfalvi A, Czirjak S, Mackie K, Vizi ES, Freund TF (2000) GABAergic interneurons are the targets of cannabinoid actions in the human hippocampus. Neuroscience 100:797–804.

    Article  PubMed  CAS  Google Scholar 

  • Katona I, Sperlágh B, Sík A, Köfalvi A, Vizi ES, Mackie K, Freund TF (1999) Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J Neurosci 19:4544–4558.

    PubMed  CAS  Google Scholar 

  • Kearn CS, Blake-Palmer K, Daniel E, Mackie K, Glass M (2004) Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? Mol Pharmacol 67:1697–1704.

    Article  CAS  Google Scholar 

  • Keay KA, Bandler R (2004) Periaqueductal gray. In: Paxinos G (ed.), The Rat Nervous System. Amsterdam: Elsevier, pp. 244–257.

    Google Scholar 

  • Kim D, Thayer SA (2001) Cannabinoids inhibit the formation of new synapses between hippocampal neurons in culture. J Neurosci 21:RC146.

    Google Scholar 

  • Kimura M, Yamada H, Matsumoto N (2003) Tonically active neurons in the striatum encode motivational contexts of action. Brain Dev Suppl 1:S20–23.

    Article  Google Scholar 

  • Kimura M, Minamimoto T, Matsumoto N, Hori Y (2004) Monitoring and switching of cortico-basal ganglia loop functions by the thalamo-striatal system. Neurosci Res 48:355–360.

    Article  PubMed  Google Scholar 

  • Knusel B, Winslow JW, Rosenthal A, Burton LE, Seid DP, Nikolics K, Hefti F (1991) Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurotrophin 3. Proc Natl Acad Sci USA 88:961–965.

    Article  PubMed  CAS  Google Scholar 

  • Köfalvi A, Oliveira CR, Cunha RA (2006a) Lack of evidence for functional TRPV1 vanilloid receptors in rat hippocampal nerve terminals. Neurosci Lett 403:151–156.

    Article  PubMed  CAS  Google Scholar 

  • Köfalvi A, Pereira MF, Rebola N, Rodrigues RJ, Oliveira CR, Cunha RA (2007) Anandamide and NADA bi-directionally modulate presynaptic Ca2+ levels and transmitter release in the hippocampus. Br J Pharmacol 151:551–563.

    Article  PubMed  CAS  Google Scholar 

  • Köfalvi A, Rebola N, Rodrigues RJ, Pereira MF, Cunha RA (2006b) Evidence for CB1Rs, but lack of evidence for presynaptic functional CB2Rs and TRPV1Rs in the hippocampus. Annual International Cannabinoid Research Society Meeting, Tihany, Hungary.

    Google Scholar 

  • Köfalvi A, Rodrigues RJ, Ledent C, Mackie K, Vizi ES, Cunha RA, Sperlagh B (2005) Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. J Neurosci 25:2874–2884.

    Article  PubMed  CAS  Google Scholar 

  • Kolb B, Gorny G, Limebeer CL, Parker LA (2006) Chronic treatment with Delta-9-tetrahydrocannabinol alters the structure of neurons in the nucleus accumbens shell and medial prefrontal cortex of rats. Synapse 60:429–436.

    Article  PubMed  CAS  Google Scholar 

  • Kovasznay B, Fleischer J, Tanenberg-Karant M, Jandorf L, Miller AD, Bromet E (1997) Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull 23:195–201.

    PubMed  CAS  Google Scholar 

  • Kraepelin E (1899) Psychiatrie, Dementia praecox. Ein Lehrbuch für Studierende und Aerzte. Leipzig: Barth.

    Google Scholar 

  • Kreitzer AC, Malenka RC (2007) Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson’s disease models. Nature 445:643–647.

    Article  PubMed  CAS  Google Scholar 

  • Kristensen K, Cadenhead KS (2007) Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res 151:151–154.

    Article  PubMed  Google Scholar 

  • Lauckner JE, Hille B, Mackie K (2005) The cannabinoid agonist WIN55, 212–2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc Natl Acad Sci USA 102:19144–19149.

    Article  PubMed  CAS  Google Scholar 

  • Leroy S, Griffon N, Bourdel MC, Olie JP, Poirier MF, Krebs MO (2001) Schizophrenia and the cannabinoid receptor type 1 (CB1): association study using a single-base polymorphism in coding exon 1. Am J Med Genet 105:749–752.

    Article  PubMed  CAS  Google Scholar 

  • Levy FO, Holtgreve-Grez H, Tasken K, Solberg R, Ried T, Gudermann T (1994) Assignment of the gene encoding the 5-HT1E serotonin receptor (S31) (locus HTR1E) to human chromosome 6q14–q15. Genomics 22:637–640.

    Article  PubMed  CAS  Google Scholar 

  • Leweke FM, Giuffrida A, Wurster U, Emrich HM, Piomelli D (1999) Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10:1665–1669.

    Article  PubMed  CAS  Google Scholar 

  • Lewis DA, Hashimoto T (2007) Deciphering the disease process of schizophrenia: the contribution of cortical GABA neurons. Int Rev Neurobiol 78:109–131.

    Article  PubMed  CAS  Google Scholar 

  • Linszen DH, Dingemans PM, Lenior ME (1994) Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 51:273–279.

    PubMed  CAS  Google Scholar 

  • Lipska BK (2004) Using animal models to test a neurodevelopmental hypothesis of schizophrenia. J Psychiatry Neurosci 29:282–286.

    PubMed  Google Scholar 

  • Long LE, Malone DT, Taylor DA (2006) Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 31:795–803.

    Article  PubMed  CAS  Google Scholar 

  • Ludwig AM (1966) Altered states of consciousness. Arch Gen Psychiatry 15:225–234.

    PubMed  CAS  Google Scholar 

  • Lupica CR, Riegel AC (2005) Endocannabinoid release from midbrain dopamine neurons: a potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacology 48:1105–1116.

    Article  PubMed  CAS  Google Scholar 

  • Luria AR (1973) The Working Brain: An Introduction to Neuropsychology. New York: Basic Books.

    Google Scholar 

  • MacDonald III AW, Chafee MV (2006) Translational and developmental perspective on N-methyl-D-aspartate synaptic deficits in schizophrenia. Dev Psychopathol 18:853–876.

    PubMed  Google Scholar 

  • Macleod J, Davey Smith G, Hickman M (2006) Does cannabis use cause schizophrenia? Lancet 367:1055.

    Article  PubMed  Google Scholar 

  • Maeda K, Sugino H, Hirose T, Kitagawa H, Nagai T, Mizoguchi H, Takuma K, Yamada K (2007) Clozapine prevents a decrease in neurogenesis in mice repeatedly treated with phencyclidine. J Pharmacol Sci 103:299–308.

    Article  PubMed  CAS  Google Scholar 

  • Mäki P, Veijola J, Rantakallio P, Jokelainen J, Jones PB, Isohanni M (2004) Schizophrenia in the offspring of antenatally depressed mothers: a 31-year follow-up of the Northern Finland 1966 Birth Cohort. Schizophr Res 66:79–81.

    Article  PubMed  Google Scholar 

  • Malaspina D, Dalack G, Leitman D, Corcoran C, Amador XF, Yale S, Glassman A, Gorman JM (2002) Low heart rate variability is not caused by typical neuroleptics in schizophrenia patients. CNS Spectr 7:53–57.

    PubMed  Google Scholar 

  • Maldonado R, Valverde O, Berrendero F (2006) Involvement of the endocannabinoid system in drug addiction. Trends Neurosci 29:225–232.

    Article  PubMed  CAS  Google Scholar 

  • Malone DT, Taylor DA (1999) Modulation by fluoxetine of striatal dopamine release following Delta9-tetrahydrocannabinol: a microdialysis study in conscious rats. Br J Pharmacol 128:21–26.

    Article  PubMed  CAS  Google Scholar 

  • Mamounas LA, Blue ME, Siuciak JA, Altar CA (1995) Brain-derived neurotrophic factor promotes the survival and sprouting of serotonergic axons in rat brain. J Neurosci 15:7929–7939.

    PubMed  CAS  Google Scholar 

  • Martinez-Gras I, Hoenicka J, Ponce G, Rodriguez-Jimenez R, Jimenez-Arriero MA, Perez-Hernandez E, Ampuero I, Ramos-Atance JA, Palomo T, Rubio G (2006) (AAT)n repeat in the cannabinoid receptor gene, CNR1: association with schizophrenia in a Spanish population. Eur Arch Psychiatry Clin Neurosci 256:437–441.

    Article  PubMed  Google Scholar 

  • Massi P, Vaccani A, Parolaro D (2006) Cannabinoids, immune system and cytokine network. Curr Pharm Des 12:3135–3146.

    Article  PubMed  CAS  Google Scholar 

  • Mathers DC, Ghodse AH (1992) Cannabis and psychotic illness. Br J Psychiatry 161:648–653.

    Article  PubMed  CAS  Google Scholar 

  • Mato S, Chevaleyre V, Robbe D, Pazos A, Castillo PE, Manzoni OJ (2004) A single in-vivo exposure to delta 9THC blocks endocannabinoid-mediated synaptic plasticity. Nat Neurosci 7:585–586.

    Article  PubMed  CAS  Google Scholar 

  • Mato S, Robbe D, Puente N, Grandes P, Manzoni OJ (2005) Presynaptic homeostatic plasticity rescues long-term depression after chronic Delta 9-tetrahydrocannabinol exposure. J Neurosci 25:11619–11627.

    Article  PubMed  CAS  Google Scholar 

  • McGrath JJ (2006) Variations in the incidence of schizophrenia: data versus dogma. Schizophr Bull 32:195–197.

    Article  PubMed  Google Scholar 

  • McGuire PK, Jones P, Harvey I, Bebbington P, Toone B, Lewis S, Murray RM (1994) Cannabis and acute psychosis. Schizophr Res 13:161–167.

    Article  PubMed  CAS  Google Scholar 

  • McGuire PK, Jones P, Harvey I, Williams M, McGuffin P, Murray RM (1995) Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr Res 15:277–281.

    Article  PubMed  CAS  Google Scholar 

  • Mechri A, Saoud M, Khiari G, d’Amato T, Dalery J, Gaha L (2001) Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine. Encephale 27:53–59.

    PubMed  CAS  Google Scholar 

  • Meck WH (1996) Neuropharmacology of timing and time perception. Cogn Brain Res 3:227–242.

    Article  CAS  Google Scholar 

  • Melges FT (1982) Time and the Inner Future–A Temporal Approach to Psychiatric Disorders. New York: Wiley.

    Google Scholar 

  • Melis M, Gessa GL, Diana M (2000) Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain. Prog Neuropsychopharmacol Biol Psychiatry 24:993–1006.

    Article  PubMed  CAS  Google Scholar 

  • Melis M, Perra S, Muntoni AL, Pillolla G, Lutz B, Marsicano G, Di Marzo V, Gessa GL, Pistis M (2004a) Prefrontal cortex stimulation induces 2-arachidonoyl-glycerol-mediated suppression of excitation in dopamine neurons. J Neurosci 24:10707–10715.

    Article  PubMed  CAS  Google Scholar 

  • Melis M, Pistis M, Perra S, Muntoni AL, Pillolla G, Gessa GL (2004b) Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J Neurosci 24:53–62.

    Article  PubMed  CAS  Google Scholar 

  • Meyer-Lindenberg A, Straub RE, Lipska BK, Verchinski BA, Goldberg T, Callicott JH, Egan MF, Huffaker SS, Mattay VS, Kolachana B, Kleinman JE, Weinberger DR (2007) Genetic evidence implicating DARPP-32 in human frontostriatal structure, function, and cognition. J Clin Invest 117:672–682.

    Article  PubMed  CAS  Google Scholar 

  • Minamimoto T, Hori Y, Kimura M (2005) Complementary process to response bias in the centromedian nucleus of the thalamus. Science 308:1798–1801.

    Article  PubMed  CAS  Google Scholar 

  • Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P (2001) Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry 6:293–301.

    Article  PubMed  CAS  Google Scholar 

  • Misslin R (2003) The defense system of fear: behavior and neurocircuitry. Neurophysiol Clin 33:55–66.

    Article  PubMed  Google Scholar 

  • Moreira FA, Guimarães FS (2005) Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol 512:199–205.

    Article  PubMed  CAS  Google Scholar 

  • Mouri A, Noda Y, Noda A, Nakamura T, Tokura T, Yura Y, Nitta A, Furukawa H, Nabeshima T (2007) Involvement of a dysfunctional dopamine-D1/NMDA-NR1 and CaMKII pathway in the impairment of latent learning in a model of schizophrenia induced by phencyclidine. Mol Pharmacol doi:10.1124/mol.106.032961.

    Google Scholar 

  • Muller N, Riedel M, Gruber R, Ackenheil M, Schwarz MJ (2000) Immune system and schizophrenia. An integrative view. Ann NY Acad Sci 917:456–467.

    Article  PubMed  CAS  Google Scholar 

  • Munson R, Ruchkin DS, Ritter W, Sutton S, Squires NK (1984) The relation of P3b to prior events and future behavior. Biol Psychol 19:1–29.

    Article  PubMed  CAS  Google Scholar 

  • Narr KL, Bilder RM, Toga AW, Woods RP, Rex DE, Szeszko PR, Robinson D, Sevy S, Gunduz-Bruce H, Wang YP, DeLuca H, Thompson PM (2005a) Mapping cortical thickness and gray matter concentration in first episode schizophrenia. Cereb Cortex 15:708–719.

    Article  PubMed  Google Scholar 

  • Narr KL, Cannon TD, Woods RP, Thompson PM, Kim S, Asunction D, van Erp TG, Poutanen VP, Huttunen M, Lonnqvist J, Standerksjold-Nordenstam CG, Kaprio J, Mazziotta JC, Toga AW (2002) Genetic contributions to altered callosal morphology in schizophrenia. J Neurosci 22:3720–3729.

    PubMed  CAS  Google Scholar 

  • Narr KL, Thompson PM, Szeszko P, Robinson D, Jang S, Woods RP, Kim S, Hayashi KM, Asunction D, Toga AW, Bilder RM (2004) Regional specificity of hippocampal volume reductions in first-episode schizophrenia. Neuroimage 21:1563–1575.

    Article  PubMed  Google Scholar 

  • Narr KL, Toga AW, Szeszko P, Thompson PM, Woods RP, Robinson D, Sevy S, Wang Y, Schrock K, Bilder RM (2005b) Cortical thinning in cingulate and occipital cortices in first episode schizophrenia. Biol Psychiatry 58:32–40.

    Article  PubMed  Google Scholar 

  • Narushima M, Uchigashima M, Fukaya M, Matsui M, Manabe T, Hashimoto K, Watanabe M, Kano M (2007) Tonic enhancement of endocannabinoid-mediated retrograde suppression of inhibition by cholinergic interneuron activity in the striatum. J Neurosci 27:496–506.

    Article  PubMed  CAS  Google Scholar 

  • Negrete JC (1989) Cannabis and schizophrenia. Br J Addict 84:349–351.

    Article  PubMed  CAS  Google Scholar 

  • Newell KA, Deng C, Huang XF (2006) Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp Brain Res 172:556–560.

    Article  PubMed  CAS  Google Scholar 

  • Nieuwenhuys R, Voogd J, van Huijzen Ch (1988) The Human Central Nervous System. Berlin: Springer.

    Google Scholar 

  • Olincy A, Harris JG, Johnson LL, Pender V, Kongs S, Allensworth D, Ellis J, Zerbe GO, Leonard S, Stevens KE, Stevens JO, Martin L, Adler LE, Soti F, Kem WR, Freedman R (2006) Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. Arch Gen Psychiatry 63:630–638.

    Article  PubMed  CAS  Google Scholar 

  • Olincy A, Johnson LL, Ross RG (2003) Differential effects of cigarette smoking on performance of a smooth pursuit and a saccadic eye movement task in schizophrenia. Psychiatry Res 117:223–236.

    Article  PubMed  Google Scholar 

  • Olney JW, Farber NB (1995) Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52:998–1007.

    PubMed  CAS  Google Scholar 

  • Ouimet CC, Langley-Guillion KC, Greengard P (1998) Quantitative immunochemistry of DARPP-32-expressing neurons in the rat caudatoputamen. Brain Res 808:8–12.

    Article  PubMed  CAS  Google Scholar 

  • Oz M, Ravindran R, Zhang L, Morales M (2003) Endogenous cannabinoid, anandamide inhibits neuronal nicotinic acethylcholine receptor-mediated responses in Xenopus oocytes. J Pharmacol Exp Ther 306:1003–1010.

    Article  PubMed  CAS  Google Scholar 

  • Oz M, Zhang L, Ravindran A, Morales M, Lupica CR (2004) Differential effects of endogenous and synthetic cannabinoids on alpha7-nicotinic acetylcholine receptor-mediated responses in Xenopus Oocytes. J Pharmacol Exp Ther 310:1152–1160.

    Article  PubMed  CAS  Google Scholar 

  • Pearlman RJ, Aubrey KR, Vandenberg RJ (2003) Arachidonic acid and anandamide have opposite modulatory actions at the glycine transporter, GLYT1a. J Neurochem 84:592–601.

    Article  PubMed  CAS  Google Scholar 

  • Pereira DB, Rebola N, Rodrigues RJ, Cunha RA, Carvalho AP, Duarte CB (2006) Trkb receptors modulation of glutamate release is limited to a subset of nerve terminals in the adult rat hippocampus. J Neurosci Res 83:832–844.

    Article  PubMed  CAS  Google Scholar 

  • Pertwee RG (2006) Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 147:S163–S171.

    Article  PubMed  CAS  Google Scholar 

  • Pichat P, Bergis OE, Terranova JP, Urani A, Duarte C, Santucci V, Gueudet C, Voltz C, Steinberg R, Stemmelin J, Oury-Donat F, Avenet P, Griebel G, Scatton B (2007) SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 32:17–34.

    Article  PubMed  CAS  Google Scholar 

  • Pistis M, Porcu G, Melis M, Diana M, Gessa GL (2001) Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation. Eur J Neurosci 14:96–102.

    Article  PubMed  CAS  Google Scholar 

  • Ponce G, Hoenicka J, Rubio G, Ampuero I, Jimenez-Arriero MA, Rodriguez-Jimenez R, Palomo T, Ramos JA (2003) Association between cannabinoid receptor gene (CNR1) and childhood attention deficit/hyperactivity disorder in Spanish male alcoholic patients. Mol Psychiatry 8:466–467.

    Article  PubMed  CAS  Google Scholar 

  • Power JM, Sah P (2007) Distribution of IP3-mediated calcium responses and their role in nuclear signaling in rat basolateral amygdala neurons. J Physiol 580:835–857.

    Article  PubMed  CAS  Google Scholar 

  • Price DA, Owens WA, Gould GG, Frazer A, Roberts JL, Daws LC, Giuffrida A (2007a) CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum. J Neurochem 101:389–396.

    Article  PubMed  CAS  Google Scholar 

  • Price G, Cercignani M, Parker GJ, Altmann DR, Barnes TR, Barker GJ, Joyce EM, Ron MA (2007) Abnormal brain connectivity in first-episode psychosis: A diffusion MRI tractography study of the corpus callosum. Neuroimage 35:458–466.

    Article  PubMed  Google Scholar 

  • Pryor SR (2000) Is platelet release of 2-arachidonoyl-glycerol a mediator of cognitive deficits? An endocannabinoid theory of schizophrenia and arousal. Med Hypotheses 55:494–501.

    Article  PubMed  CAS  Google Scholar 

  • Ragozzino ME, Choi D (2004) Dynamic changes in acetylcholine output in the medial striatum during place reversal learning. Learn Mem 11:70–77.

    Article  PubMed  Google Scholar 

  • Rashid AJ, So CH, Kong MM, Furtak T, El-Ghundi M, Cheng R, O’Dowd BF, George SR (2007) D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc Natl Acad Sci USA 104:654–659.

    Article  PubMed  CAS  Google Scholar 

  • Risold PY (2004) The septal region. In: Paxinos G (ed.), The Rat Nervous System. Amsterdam: Elsevier, pp. 602–636.

    Google Scholar 

  • Rizzolatti G, Gallese V (2003) Mirror neurons. In: Nadel L (ed.), Encyclopedia of Cognitive Science. London: Nature PG, Vol. III, pp. 37–42.

    Google Scholar 

  • Ronesi J, Lovinger DM (2005) Induction of striatal long-term synaptic depression by moderate frequency activation of cortical afferents in rat. J Physiol 562:245–256.

    Article  PubMed  CAS  Google Scholar 

  • Roopun AK, Middleton SJ, Cunningham MO, LeBeau FE, Bibbig A, Whittington MA, Traub RD (2006) A beta2-frequency (20–30 Hz) oscillation in nonsynaptic networks of somatosensory cortex. Proc Natl Acad Sci USA 103:15646–15650.

    Article  PubMed  CAS  Google Scholar 

  • Samejima K, Ueda Y, Doya K, Kimura M (2005) Representation of action-specific reward values in the striatum. Science 310:1337–1340.

    Article  PubMed  CAS  Google Scholar 

  • Sarter M, Bruno JP (2000) Cortical cholinergic inputs mediating arousal, attentional processing and dreaming: differential afferent regulation of the basal forebrain by telencephalic and brainstem afferents. Neuroscience 95:933–952.

    Article  PubMed  CAS  Google Scholar 

  • Saulskaya NB (2000) Volume transmission in the striatum as constituting information processing In: Miller R, Ivanitsky AM, Balaban PM (eds.), Complex Brain Functions–Conceptual Advances in Russian Neuroscience. Singapore: OPA, pp. 1–19.

    Google Scholar 

  • Schneier FR, Siris SG (1987) A review of psychoactive substance use and abuse in schizophrenia. Patterns of drug choice. J Nerv Ment Dis 175:641–652.

    Article  PubMed  CAS  Google Scholar 

  • Seeman P (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1:133–152.

    Article  PubMed  CAS  Google Scholar 

  • Semple DM, McIntosh AM, Lawrie SM (2005) Cannabis as a risk factor for psychosis: systematic review. J Psychopharmacol 19:187–194.

    Article  PubMed  Google Scholar 

  • Semple DM, Ramsden F, McIntosh AM. (2003) Reduced binocular depth inversion in regular cannabis users. Pharmacol Biochem Behav 75:789–793.

    Article  PubMed  CAS  Google Scholar 

  • Shapovalova KB (2000) The striatal cholinergic system and instrumental behaviour. In: Miller R, Ivanitsky AM, Balaban PM (eds.), Complex Brain Functions–Conceptual Advances in Russian Neuroscience. Singapore: OPA, pp. 263–288.

    Google Scholar 

  • Sharp FR, Butman M, Koistinaho J, Aardalen K, Nakki R, Massa SM, Swanson RA, Sagar SM (1994) Phencyclidine induction of the hsp 70 stress gene in injured pyramidal neurons is mediated via multiple receptors and voltage gated calcium channels. Neuroscience 62:1079–1092.

    Article  PubMed  CAS  Google Scholar 

  • Shearn CR, Fitzgibbons DJ (1972) Patterns of drug use in a population of youthful psychiatric patients. Am J Psychiatry 128:1381–1387.

    PubMed  CAS  Google Scholar 

  • Shenton ME, Dickey CC, Frumin M, McCarley RW (2001) A review of MRI findings in schizophrenia. Schizophr Res 49:1–52.

    Article  PubMed  CAS  Google Scholar 

  • Shergill SS, Samson G, Bays PM, Frith CD, Wolpert DM (2005) Evidence for sensory prediction deficits in schizophrenia. Am J Psychiatry 162:2384–2386.

    Article  PubMed  Google Scholar 

  • Simmons JM, Richmond BJ (2007) Dynamic changes in representations of preceding and upcoming reward in monkey orbitofrontal cortex. Cereb Cortex doi:10.1093/cercor/bhm034.

    Google Scholar 

  • Simonyi A, Schachtman TR, Christoffersen GR (2005) The role of metabotropic glutamate receptor 5 in learning and memory processes. Drug News Perspect 18:353–361.

    Article  PubMed  CAS  Google Scholar 

  • Skosnik PD, Krishnan GP, Aydt EE, Kuhlenshmidt HA, O’Donnell BF (2006) Psychophysiological evidence of altered neural synchronization in cannabis use: relationship to schizotypy. Am J Psychiatry 163:1798–1805.

    Article  PubMed  Google Scholar 

  • Smesny S, Rosburg T, Baur K, Rudolph N, Sauer H (2007) Cannabinoids influence lipid-arachidonic acid pathways in schizophrenia. Neuropsychopharmacology 32:2067–2073.

    Article  PubMed  CAS  Google Scholar 

  • Solowij N, Michie PT (2007) Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia? J Psychiatry Neurosci 32:30–52.

    PubMed  Google Scholar 

  • Solowij N, Michie PT, Fox AM (1991) Effect of long-term cannabis use on selective attention: an event-related potential study. Pharmacol Biochem Behav 40:683–688.

    Article  PubMed  CAS  Google Scholar 

  • Steffens M, Feuerstein TJ (2004) Receptor-independent depression of DA and 5-HT uptake by cannabinoids in rat neocortex–involvement of Na+/K+-ATPase. Neurochem Int 44:529–538.

    Article  PubMed  CAS  Google Scholar 

  • Stein BE, Meredith MA (1993) The Merging of the Senses. Cambridge: MIT.

    Google Scholar 

  • Suh BC, Hille B (2007) Regulation of KCNQ channels by manipulation of phosphoinositides. J Physiol 582:911–916.

    Article  PubMed  CAS  Google Scholar 

  • Sundram S, Copolov D, Dean B (2005) Clozapine decreases [3H]CP55940 binding to the cannabinoid 1 receptor in the rat nucleus accumbens. Naunyn Schmiedebergs Arch Pharmacol 371:428–433.

    Article  PubMed  CAS  Google Scholar 

  • Surmeier DJ, Ding J, Day M, Wang Z, Shen W (2007) D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons. Trends Neurosci 30:228–235.

    Article  PubMed  CAS  Google Scholar 

  • Swanson LW (2000) Cerebral hemisphere regulation of motivated behavior. Brain Res 886:113–164.

    Article  PubMed  CAS  Google Scholar 

  • Szabo B, Siemes S, Wallmichrath I (2002) Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids. Eur J Neurosci 15:2057–2061.

    Article  PubMed  Google Scholar 

  • Szeszko PR, Robinson DG, Sevy S, Kumra S, Rupp CI, Betensky JD, Lencz T, Ashtari M, Kane JM, Malhotra AK, Gunduz-Bruce H, Napolitano B, Bilder RM (2007) Anterior cingulate grey-matter deficits and cannabis use in first-episode schizophrenia. Br J Psychiatry 190:230–236.

    Article  PubMed  Google Scholar 

  • Talbot K, Arnold SA (2002) The parahippocampal region in schizophrenia. In: Witter M, Wouterlood F (eds.), The Parahippocampal Region–Organization and Role in Cognitive Function. Oxford: Oxford University Press, pp. 297–320.

    Google Scholar 

  • Tappe A, Kuner R (2006) Regulation of motor performance and striatal function by synaptic scaffolding proteins of the Homer1 family. Proc Natl Acad Sci USA 103:774–779.

    Article  PubMed  CAS  Google Scholar 

  • Tendolkar I, Weis S, Guddat O, Fernandez G, Brockhaus-Dumke A, Specht K, Klosterkotter J, Reul J, Ruhrmann S (2004) Evidence for a dysfunctional retrosplenial cortex in patients with schizophrenia: a functional magnetic resonance imaging study with a semantic-perceptual contrast. Neurosci Lett 369:4–8.

    Article  PubMed  CAS  Google Scholar 

  • Tsai SJ, Wang YC, Hong CJ (2000) Association study of a cannabinoid receptor gene (CNR1) polymorphism and schizophrenia. Psychiatr Genet 10:149–151.

    Article  PubMed  CAS  Google Scholar 

  • Turner WM, Tsuang MT (1990) Impact of substance abuse on the course and outcome of schizophrenia. Schizophr Bull 16:87–95.

    PubMed  CAS  Google Scholar 

  • Uchigashima M, Narushima M, Fukaya M, Katona I, Kano M, Watanabe M (2007) Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci 27:3663–3676.

    Article  PubMed  CAS  Google Scholar 

  • Ujike H, Morita Y (2004) New perspectives in the studies on endocannabinoid and cannabis: cannabinoid receptors and schizophrenia. J Pharmacol Sci 96:376–381.

    Article  PubMed  CAS  Google Scholar 

  • Ujike H, Takaki M, Nakata K, Tanaka Y, Takeda T, Kodama M, Fujiwara Y, Sakai A, Kuroda S (2002) CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry 7:515–518.

    Article  PubMed  CAS  Google Scholar 

  • van Os J, Bak M, Hanssen M, Bijl RV, de Graaf R, Verdoux H (2002) Cannabis use and psychosis: a longitudinal population-based study. Am J Epidemiol 156:319–327.

    Article  PubMed  Google Scholar 

  • Vignal JP, Maillard L, McGonigal A, Chauvel P (2007) The dreamy state: hallucinations of autobiographic memory evoked by temporal lobe stimulations and seizures. Brain 130:88–99.

    Article  PubMed  Google Scholar 

  • Virchow R (1847) Standpoints in scientific medicine. In: Rather LJ (ed.), Diseases, Life and Man; Selected Essays by Rudolf Virchow. Stanford: Stanford University Press.

    Google Scholar 

  • Voruganti LN, Slomka P, Zabel P, Mattar A, Awad AG (2001) Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res 107:173–177.

    Article  PubMed  CAS  Google Scholar 

  • Wang Y, Goldman-Rakic PS (2004) D2 receptor regulation of synaptic burst firing in prefrontal cortical pyramidal neurons. Proc Natl Acad Sci USA 101:5093–5098.

    Article  PubMed  CAS  Google Scholar 

  • Weiser M, Knobler HY, Noy S, Kaplan Z (2002) Clinical characteristics of adolescents later hospitalized for schizophrenia. Am J Med Genet 114:949–955.

    Article  PubMed  Google Scholar 

  • Weiser M, Noy S (2005) Interpreting the association between cannabis use and increased risk for schizophrenia. Dialogues Clin Neurosci 7:81–85.

    PubMed  Google Scholar 

  • Wettschureck N, van der Stelt M, Tsubokawa H, Krestel H, Moers A, Petrosino S, Schutz G, Di Marzo V, Offermanns S (2006) Forebrain-specific inactivation of Gq/G11 family G proteins results in age-dependent epilepsy and impaired endocannabinoid formation. Mol Cell Biol 26:5888–5894.

    Article  PubMed  CAS  Google Scholar 

  • Yamasue H, Iwanami A, Hirayasu Y, Yamada H, Abe O, Kuroki N, Fukuda R, Tsujii K, Aoki S, Ohtomo K, Kato N, Kasai K (2004) Localized volume reduction in prefrontal, temporolimbic, and paralimbic regions in schizophrenia: an MRI parcellation study. Psychiatry Res 131:195–207.

    Article  PubMed  Google Scholar 

  • Yano M, Steiner H (2005) Methylphenidate (Ritalin) induces Homer 1a and zif 268 expression in specific corticostriatal circuits. Neuroscience 132:855–865.

    Article  PubMed  CAS  Google Scholar 

  • Yeomans JS (1995) Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. Neuropsychopharmacology 12:3–16.

    Article  PubMed  CAS  Google Scholar 

  • Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G (2002) Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ 325:1199.

    Article  PubMed  Google Scholar 

  • Zavitsanou K, Garrick T, Huang XF (2004) Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28:355–360.

    Article  PubMed  CAS  Google Scholar 

  • Zhang PW, Isighuro H, Ohtsuki T, Hess J, Carillo F, Walther D, Onaivi ES, Arinami T, Uhl GR (2004) Human cannabinoid receptor 1:5¢ exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysusbstance abuse. Mol Psychiatry 9:916–931.

    Article  PubMed  CAS  Google Scholar 

  • Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimaraes FS (2006) Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 39:421–429.

    Article  PubMed  CAS  Google Scholar 

  • Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R (1995) Antipsychotic effect of cannabidiol. J Clin Psychiatry 56:485–486.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Praxis für Innere Medizin, Soodstrasse 13, 8134, Adliswil, Switzerland

    Markus Fritzsche

Authors
  1. Attila Köfalvi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Markus Fritzsche
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Center for Neurosciences of Coimbra, University of Coimbra, Coimbra, 3000-045, Portugal

    Attila Köfalvi (Faculty of Medicine) (Faculty of Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer

About this chapter

Cite this chapter

Köfalvi, A., Fritzsche, M. (2008). The Endocannabinoid System is a Major Player in Schizophrenia. In: Köfalvi, A. (eds) Cannabinoids and the Brain. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-74349-3_22

Download citation

Publish with us

Policies and ethics

Search

Navigation